



## Kura Oncology to Participate in Three Upcoming Investor Conferences

May 26, 2022

SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in three upcoming investor conferences:

- A virtual fireside chat at Cowen's 3<sup>rd</sup> Annual Oncology Innovation Summit at 3:30 p.m. ET / 12:30 p.m. PT on June 2, 2022;
- A fireside chat at the Jefferies Healthcare Conference in New York at 10:30 a.m. ET / 7:30 a.m. PT on June 8, 2022; and
- A fireside chat at the JMP Securities Life Sciences Conference in New York at 2:30 p.m. ET / 11:30 a.m. PT on June 16, 2022.

Audio webcasts will be available in the Investors section of Kura's website at [www.kuraoncology.com](http://www.kuraoncology.com), with archived replays available following each event.

### About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company's pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib (KO-539), a potent and selective menin inhibitor, is currently in a Phase 1b clinical trial (KOMET-001) for patients with relapsed/refractory AML, including patients with NPM1 mutations or KMT2A rearrangements. Tipifarnib, a potent, selective and orally bioavailable FTI, has received Breakthrough Therapy Designation for the treatment of patients with HRAS mutant HNSCC and is currently in a registration-directed trial (AIM-HN) in patients with this devastating disease. In addition, Kura is conducting a Phase 1/2 trial (KURRENT-HN) of tipifarnib in combination with the PI3K $\alpha$  inhibitor alpelisib to address larger genetic subsets of HNSCC patients, including those whose tumors are dependent on HRAS and/or PI3K $\alpha$  pathways. The Company is also preparing to initiate a Phase 1 trial (KURRENT-LUNG) of tipifarnib in combination with osimertinib in treatment-naïve locally advanced/metastatic EGFR mutated NSCLC. Kura intends to perform initial clinical evaluation with tipifarnib while in parallel advancing KO-2806, the Company's next-generation FTI, through IND-enabling studies. For additional information, please visit Kura's website at [www.kuraoncology.com](http://www.kuraoncology.com).

### Contacts

#### Company:

Pete De Spain  
Senior Vice President, Investor Relations &  
Corporate Communications  
(858) 500-8803  
[pete@kuraoncology.com](mailto:pete@kuraoncology.com)

#### Investors:

Robert H. Uhl  
Managing Director  
ICR Westwicke  
(858) 356-5932  
[robert.uhl@westwicke.com](mailto:robert.uhl@westwicke.com)

#### Media:

Jason Spark  
Managing Director  
Canale Communications  
(619) 849-6005  
[jason@canalecomm.com](mailto:jason@canalecomm.com)



Source: Kura Oncology, Inc.